Core Viewpoint - The non-executive director Guo Huaqing increased his stake in Kintor Pharmaceutical-B (02171) by purchasing 70,000 shares at a price of HKD 14.8 per share, totaling HKD 1.036 million, raising his total holdings to approximately 218 million shares, which represents a 37.72% ownership [1] Summary by Category - **Share Purchase Details** - Guo Huaqing acquired 70,000 shares of Kintor Pharmaceutical-B at HKD 14.8 each, amounting to HKD 1.036 million [1] - **Post-Purchase Holdings** - After the purchase, Guo's total shareholding in the company is about 218 million shares, equating to a 37.72% ownership stake [1]

Core Viewpoint - The non-executive director Guo Huaqing increased his stake in Kintor Pharmaceutical-B (02171) by purchasing 70,000 shares at a price of HKD 14.8 per share, totaling HKD 1.036 million, raising his total holdings to approximately 218 million shares, which represents 37.72% of the company [1] Summary by Category - **Share Purchase Details** - Guo Huaqing acquired 70,000 shares of Kintor Pharmaceutical-B at HKD 14.8 each [1] - The total investment amounted to HKD 1.036 million [1] - **Post-Purchase Holdings** - After the purchase, Guo Huaqing's total shareholding increased to approximately 218 million shares [1] - His ownership percentage in the company is now 37.72% [1]

Core Viewpoint - 科济药业 is actively repurchasing its shares to enhance shareholder value while continuing to develop innovative CAR-T therapies for unmet clinical needs [1][2] Group 1: Share Repurchase Activity - On November 6, 科济药业 announced the repurchase of 1.734 million shares at a price range of HKD 14.350 to HKD 15.8, totaling HKD 26.3078 million [1] - In the past month, the company has conducted three repurchase activities, acquiring a total of 2.189 million shares for a cumulative amount of HKD 33.9758 million [1] - The company has a repurchase plan allowing it to buy back up to 1% of its total issued shares in the open market [1] Group 2: Company Overview and Product Pipeline - 科济药业 is a biopharmaceutical company focused on developing innovative CAR-T cell therapies to address unmet clinical needs, including hematologic malignancies, solid tumors, and autoimmune diseases [1] - The company has 10 CAR-T pipeline products, including 4 autologous CAR-T and 6 universal CAR-T, all of which are self-developed with global rights [1] - The all-human BCMA autologous CAR-T product,赛恺泽, has been approved for marketing in China, while the Claudin18.2 autologous humanized CAR-T product,舒瑞基奥仑赛, is the first CAR-T product for solid tumors to submit a new drug application globally [1] Group 3: Recent R&D Achievements - On November 3, 科济药业 announced new clinical data for its universal CAR-T products, CT0596 and CT1190B, showing promising safety and efficacy signals for treating relapsed/refractory multiple myeloma and non-Hodgkin lymphoma, respectively [2] - As of June 30, 2026, the company reported cash and cash equivalents exceeding HKD 1.26 billion, indicating a strong financial position to support ongoing operations and share repurchase plans [2] - The management expressed commitment to maintaining the share repurchase program, adjusting it based on market conditions to further protect shareholder interests [2]

Core Viewpoint - On November 6, 39 Hong Kong-listed companies conducted share buybacks, totaling 23.82 million shares and an amount of HKD 160 million [1][2]. Group 1: Buyback Details - China Feihe repurchased 6.81 million shares for HKD 29.43 million, with a highest price of HKD 4.350 and a lowest price of HKD 4.290, accumulating HKD 284.38 million in buybacks for the year [1][2]. - Kintor Pharmaceutical-B bought back 1.73 million shares for HKD 26.31 million, with a highest price of HKD 15.800 and a lowest price of HKD 14.350, totaling HKD 33.98 million in buybacks for the year [1][2]. - COSCO Shipping Holdings repurchased 1.53 million shares for HKD 20.99 million, with a highest price of HKD 13.840 and a lowest price of HKD 13.570, accumulating HKD 46.58 billion in buybacks for the year [1][2]. Group 2: Buyback Rankings - The highest buyback amount on November 6 was by China Feihe at HKD 29.43 million, followed by Kintor Pharmaceutical-B at HKD 26.31 million [1][2]. - In terms of share quantity, China Feihe also led with 6.81 million shares repurchased, followed by China Petroleum & Chemical Corporation with 2.40 million shares [1][2]. Group 3: Additional Insights - The buyback by Kintor Pharmaceutical-B was noted as its first for the year [2]. - The total buyback amount for COSCO Shipping Holdings reflects its multiple buyback activities throughout the year [2].

Summary of Key Points Core Viewpoint - A total of 30 companies conducted share buybacks on November 6, 2025, with China Feihe (06186) leading in both the number of shares repurchased and the total amount spent on buybacks [1]. Group 1: Buyback Details - China Feihe (06186) repurchased 6.806 million shares for a total of 29.4298 million yuan, representing 0.746% of its total share capital [2]. - Kexin Pharmaceutical-B (02171) repurchased 1.734 million shares for 26.3078 million yuan, accounting for 0.380% of its total share capital [2]. - COSCO Shipping Holdings (01919) repurchased 1.53 million shares for 20.9869 million yuan, which is 0.409% of its total share capital [2]. Group 2: Other Notable Buybacks - Gushengtang (02273) repurchased 493,500 shares for 13.7699 million yuan, representing 3.435% of its total share capital [2]. - China Petroleum & Chemical Corporation (00386) repurchased 2.398 million shares for 10.1066 million yuan, which is 0.100% of its total share capital [2]. - Lianyi Technology-W (09959) repurchased 2.38 million shares for 7.4745 million yuan, accounting for 4.298% of its total share capital [2]. Group 3: Additional Companies - Other companies that conducted buybacks include: - Ruisheng Technology (02018) with 165,000 shares repurchased for 6.5033 million yuan [2]. - MGM China (02282) with 400,000 shares repurchased for 6.3701 million yuan [2]. - Huajian Medical (01931) with 922,000 shares repurchased for 5.9985 million yuan [2]. Group 4: Smaller Buybacks - Companies with smaller buyback amounts include: - Yidian Cloud (02416) with 130,000 shares repurchased for 264,000 yuan [3]. - International Home Retail (01373) with 150,000 shares repurchased for 118,500 yuan [3]. - Mobi Development (00947) with 70,000 shares repurchased for 1.167 million yuan [3].

Core Viewpoint - Kintor Pharmaceutical-B has conducted a share buyback on November 6, purchasing 1.734 million shares at a price range of HKD 14.350 to HKD 15.800, totaling HKD 26.3078 million [2] Summary by Category Buyback Details - The company repurchased 1.734 million shares on November 6, with a closing price of HKD 15.680, reflecting a 0.32% increase on that day [2] - The total trading volume for the day was HKD 91.6057 million [2] - Year-to-date, the company has completed three buybacks, totaling 2.189 million shares and an aggregate amount of HKD 33.9758 million [2] Buyback Breakdown | Date | Shares Repurchased (thousand) | Highest Price (HKD) | Lowest Price (HKD) | Total Amount (thousand HKD) | |------------|-------------------------------|---------------------|--------------------|------------------------------| | 2025.11.06 | 173.40 | 15.800 | 14.350 | 2630.78 | | 2025.10.23 | 20.50 | 16.700 | 16.470 | 339.82 | | 2025.10.21 | 25.00 | 17.150 | 16.990 | 426.98 | [2]

Company News - BeiGene reported total revenue of approximately $3.845 billion for the first nine months, a year-on-year increase of 43%. Adjusted net profit was approximately $693 million, marking a return to profitability. In Q3, revenue reached $1.412 billion, up 41% year-on-year, with adjusted net profit of approximately $304 million, a 489% increase year-on-year. The growth is primarily attributed to the sales increase of BeiYueZe® in the US and Europe, with the US remaining the largest market for the company. The full-year revenue guidance is set at $5.1 billion to $5.3 billion, reflecting strong growth expectations from BeiYueZe® in the US and continued expansion in Europe and other key global markets [2] - Yidu International Holdings announced an earnings upgrade, expecting a profit attributable to shareholders of approximately HKD 1.2 billion for the first half, representing an increase year-on-year [3] - Hua Hong Semiconductor reported sales revenue of $635 million for Q3 2025, a year-on-year increase of 20.7%. However, net profit decreased by 42.6% to $25.725 million [4] - Autohome's net profit attributable to the parent company for Q3 was approximately RMB 436.6 million, with online marketing and other business revenues increasing by 32.1% year-on-year [5] - Xinyi International reported a cumulative net operating income of approximately HKD 13.981 billion for the first ten months, a year-on-year decrease of about 5.3%, with October revenue at HKD 1.457 billion [6] - Dongfeng Motor Group's cumulative vehicle sales for the first ten months reached 1.501 million units, a year-on-year decline of approximately 1.6%. However, sales of new energy vehicles increased by approximately 37.1% to 421,400 units [7] - China Overseas Land & Investment reported a cumulative contracted property sales amount of approximately RMB 189.165 billion for the first ten months, a year-on-year decrease of 21.3% [8] - Poly Property Group reported a cumulative contracted sales amount of RMB 43.8 billion for the first ten months, a year-on-year decrease of 10.43% [9] - Gemdale reported a cumulative contracted sales amount of approximately RMB 9.125 billion for the first ten months, a year-on-year decrease of 43.93% [10] - Sunac China reported a cumulative contract sales amount of approximately RMB 32.77 billion for the first ten months, a year-on-year decline of 25.1% [11] - Guoyin Financial Leasing plans to purchase 1,198 units of domestic information technology computing equipment for a total consideration of RMB 1.04 billion [12] - Youjia Innovation recently received project designation notifications from a globally renowned automotive group's joint venture and luxury brand, with a total order amount of approximately RMB 320 million [13] - Swire Properties reported a rental rate of 96% for Taikoo Place in Q3, with a rental reduction of 13%. Other Swire properties had an occupancy rate of 90%, with a rental reduction of 15% [14] - Zhongshen Construction Industry plans to acquire 100% equity of Huajian Development Co., Ltd. for approximately HKD 213.6 million [15] - Hard Egg Innovation signed a memorandum of understanding with Huixin Investment to jointly develop an AIoT innovation enterprise incubation platform [16] - Damai Entertainment expects mid-term net profit to increase to no less than RMB 500 million, compared to RMB 337 million last year [17] - Cafe de Coral Group issued a profit warning, expecting mid-term profit attributable to shareholders to decline by 65% to 70% [18] - Qingci Games signed a game licensing transfer agreement with Disney, obtaining authorization to develop and publish the game "Disney: Book of Legends," expected to launch in 2026 across various regions [19] - Now Medical Technology's subsidiary signed a strategic cooperation framework agreement with Medtronic Changzhou to promote clinical applications of real-time navigation tracking endoscopic technology in China [19] - Zhaoke Ophthalmology-B signed a distribution agreement with PT FERRON for the commercialization of BRIMOCHOL PF in Indonesia, receiving an upfront payment and potential milestone payments [19] - Shoujia Technology signed a strategic framework cooperation agreement with Stardust Intelligence, covering the development of humanoid robot tendon and related fields [20] Buyback Dynamics - Helen's decided to exercise its share buyback authorization, planning to repurchase up to 127 million shares [21] - China Feihe repurchased 6.806 million shares for a total of approximately HKD 29.4298 million, with a buyback price of HKD 4.29 to HKD 4.35 [22] - Kintor Pharmaceutical repurchased 1.734 million shares for a total of approximately HKD 26.3078 million, with a buyback price of HKD 14.35 to HKD 15.8 [23] - COSCO Shipping Holdings repurchased 1.53 million shares for a total of approximately HKD 20.9869 million, with a buyback price of HKD 13.57 to HKD 13.84 [24] - Sinopec repurchased 2.398 million H-shares for a total of approximately HKD 10.1066 million, with a buyback price of HKD 4.20 to HKD 4.23 [25]

Group 1 - Company Kintor Pharmaceutical-B (02171.HK) announced a share buyback on November 6, 2023, spending HKD 26.308 million to repurchase 1.734 million shares [1]

Core Viewpoint - Kintor Pharmaceutical Co., Ltd. announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Group 1 - The company plans to repurchase 1.734 million shares at a total cost of HKD 26.3078 million [1] - The buyback is scheduled for November 6, 2025, reflecting a strategic move to enhance shareholder value [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 科濟藥業控股有限公司 呈交日期： 2025年11月6日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02171 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存 ...